poisar

Stocks · News reference

Kyntra Bio To Reduce The Maximum Aggregate Payments Under Its Royalty Financing Agreement From $125M To $65M; Co. Accelerated Payment Of $42.6M Upfront, Bringing Total Payments Made To Date To $50M; Remaining Payments, Capped At $15M, To Be Paid From 50% Of The Revenue Received From Astellas In The Astellas Territories Excluding Japan

Benzinga Newsdesk

Company reduces the maximum aggregate payments under its royalty financing agreement from $125 million to $65 million Company accelerated payment of $42.6 million upfront, bringing total payments made to date to $50

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

KYNB
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. SEC EDGAR

    8-K filing — KYNTRA BIO, INC. (KYNB)

    Filed: 2026-10-06 AccNo: 0001193125-26-415545 Size: 150 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    KYNB
  3. Na

    Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors

    Kyntra Bio announced the appointment of Andrew E. Singer, an experienced biotechnology finance executive with 25+ years in investment banking and corporate strategy, to its Board of Directors as an independent director and Audit Committee member effective October 1, 2026. Simultaneously, Maykin Ho stepped down after nearly eight years of service. Singer's appointment is expected to strengthen the company's financial position as it advances its rare disease and oncology pipeline.

    KYNB